Sundeep Khosla

List of Publications by Year in Descending Order

463 papers	45,995 citations	106 h-index	202 g-index
505 ext. papers	52,128 ext. citations	7.6 avg, IF	7.74 L-index

#	Paper	IF	Citations
463	Osteoporosis and bone loss **2022**, 335-361		
462	Orally-active, clinically-translatable senolytics restore αKlotho in mice and humans.. *EBioMedicine*, **2022**, 103912	8.8	1
461	Bone marrow adiposity in models of radiation- and aging-related bone loss is dependent on cellular senescence.. *Journal of Bone and Mineral Research*, **2022**,	6.3	1
460	Targeted clearance of p21- but not p16-positive senescent cells prevents radiation-induced osteoporosis and increased marrow adiposity.. *Aging Cell*, **2022**, e13602	9.9	3
459	Skeletal Aging. *Mayo Clinic Proceedings*, **2022**, 97, 1194-1208	6.4	2
458	Bone microarchitecture phenotypes identified in older adults are associated with different levels of osteoporotic fracture risk.. *Journal of Bone and Mineral Research*, **2021**,	6.3	2
457	Modulation of fracture healing by the transient accumulation of senescent cells. *ELife*, **2021**, 10,	8.9	2
456	Neutrophils induce paracrine telomere dysfunction and senescence in ROS-dependent manner. *EMBO Journal*, **2021**, 40, e106048	13	26
455	Risk of bone fractures after the diagnosis of adrenal adenomas: a population-based cohort study. *European Journal of Endocrinology*, **2021**, 184, 597-606	6.5	3
454	Global and Spatial Compartmental Interrelationships of Bone Density, Microstructure, Geometry and Biomechanics in the Distal Radius in a CollesPFracture Study Using HR-pQCT. *Frontiers in Endocrinology*, **2021**, 12, 568454	5.7	0
453	Opportunistic application of phantom-less calibration methods for fracture risk prediction using QCT/FEA. *European Radiology*, **2021**, 31, 9428-9435	8	3
452	Senolytics reduce coronavirus-related mortality in old mice. *Science*, **2021**, 373,	33.3	60
451	Establishment of normative biometric data for body composition based on computed tomography in a North American cohort. *Clinical Nutrition*, **2021**, 40, 2435-2442	5.9	0
450	Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span. *Annual Review of Pharmacology and Toxicology*, **2021**, 61, 779-803	17.9	52
449	Estrogen deficiency and the pathogenesis of osteoporosis **2021**, 773-797		0
448	Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction. *European Heart Journal*, **2021**, 42, 1595-1605	9.5	25
447	Senescent cells exacerbate chronic inflammation and contribute to periodontal disease progression in old mice. *Journal of Periodontology*, **2021**, 92, 1483-1495	4.6	6

446	Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained. *Journal of Bone and Mineral Research*, **2021**, 36, 236-243	6.3	4
445	Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials in the COVID era. *Journal of the American Geriatrics Society*, **2021**, 69, 3023-3033	5.6	9
444	Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus. *Nature Reviews Endocrinology*, **2021**, 17, 685-697	15.2	6
443	Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project. *Journal of Bone and Mineral Research*, **2021**,	6.3	2
442	The role of senolytics in osteoporosis and other skeletal pathologies. *Mechanisms of Ageing and Development*, **2021**, 199, 111565	5.6	4
441	Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. *Journal of Orthopaedic Trauma*, **2020**, 34, e125-e141	3.1	6
440	Managing fragility fractures during the COVID-19 pandemic. *Nature Reviews Endocrinology*, **2020**, 16, 467-468	15.2	27
439	Determinants of Bone Material Strength and Cortical Porosity in Patients with Type 2 Diabetes Mellitus. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	13
438	Male mice with elevated C-type natriuretic peptide-dependent guanylyl cyclase-B activity have increased osteoblasts, bone mass and bone strength. *Bone*, **2020**, 135, 115320	4.7	7
437	The Impact of Mild Autonomous Cortisol Secretion on Bone Turnover Markers. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	8
436	The role of cellular senescence in ageing and endocrine disease. *Nature Reviews Endocrinology*, **2020**, 16, 263-275	15.2	133
435	Estrogen Versus FSH Effects on Bone Metabolism: Evidence From Interventional Human Studies. *Endocrinology*, **2020**, 161,	4.8	7
434	Posterior single-stepping thresholds are prospectively related to falls in older women. *Aging Clinical and Experimental Research*, **2020**, 32, 2507-2515	4.8	5
433	Targeted Reduction of Senescent Cell Burden Alleviates Focal Radiotherapy-Related Bone Loss. *Journal of Bone and Mineral Research*, **2020**, 35, 1119-1131	6.3	40
432	Accelerated osteocyte senescence and skeletal fragility in mice with type 2 diabetes. *JCI Insight*, **2020**, 5,	9.9	25
431	SUN-LB68 Advanced Glycation Endproducts Are Associated With Worse Bone Material Strength in Older Adults With and Without Type 2 Diabetes. *Journal of the Endocrine Society*, **2020**, 4,	0.4	1
430	The microbiome adds to the complexity of parathyroid hormone action on bone. *Journal of Clinical Investigation*, **2020**, 130, 1615-1617	15.9	1
429	SUN-381 Cortical Porosity Is Associated with Peripheral Small Vessel Disease in Adult Patients with Type 2 Diabetes. *Journal of the Endocrine Society*, **2020**, 4,	0.4	78

428	Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. *Nature Communications*, **2020**, 11, 87	17.4	53
427	LPS-induced premature osteocyte senescence: Implications in inflammatory alveolar bone loss and periodontal disease pathogenesis. *Bone*, **2020**, 132, 115220	4.7	25
426	Unsupervised machine learning for the discovery of latent disease clusters and patient subgroups using electronic health records. *Journal of Biomedical Informatics*, **2020**, 102, 103364	10.2	24
425	Estrogens and progestins **2020**, 827-837		
424	Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 894-902	18.1	40
423	Comparison of Vertebral and Femoral Strength Between White and Asian Adults Using Finite Element Analysis of Computed Tomography Scans. *Journal of Bone and Mineral Research*, **2020**, 35, 2345-2354	6.3	5
422	Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 672-682	18.1	40
421	Osteocyte Cellular Senescence. *Current Osteoporosis Reports*, **2020**, 18, 559-567	5.4	4
420	Periodontal Disease and Senescent Cells: New Players for an Old Oral Health Problem?. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	7
419	Early effects of androgen deprivation on bone and mineral homeostasis in adult men: a prospective cohort study. *European Journal of Endocrinology*, **2020**, 183, 181-189	6.5	3
418	Biology and Clinical Aspects of Estrogen Action on Bone **2020**, 524-532		
417	Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. *Journal of Bone and Mineral Research*, **2020**, 35, 36-52	6.3	63
416	Reducing Senescent Cell Burden in Aging and Disease. *Trends in Molecular Medicine*, **2020**, 26, 630-638	11.5	47
415	Development and Application of Mass Spectroscopy Assays for N□(1-Carboxymethyl)-L-Lysine and Pentosidine in Renal Failure and Diabetes. *journal of applied laboratory medicine, The*, **2020**, 5, 558-568	2	5
414	Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. *EBioMedicine*, **2019**, 47, 446-456	8.8	356
413	Personalising osteoporosis treatment for patients at high risk of fracture. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 739-741	18.1	5
412	Cellular senescence in bone. *Bone*, **2019**, 121, 121-133	4.7	68
411	A Lot of Progress, With More to Be Done: A Response to NIH Pathways to Prevention Report "Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention". *Journal of Bone and Mineral Research*, **2019**, 34, 1549-1551	6.3	4

410	Independent Roles of Estrogen Deficiency and Cellular Senescence in the Pathogenesis of Osteoporosis: Evidence in Young Adult Mice and Older Humans. *Journal of Bone and Mineral Research*, **2019**, 34, 1407-1418	6.3	35
409	Circulating Osteogenic Progenitor Cells in Mild, Moderate, and Severe Aortic Valve Stenosis. *Mayo Clinic Proceedings*, **2019**, 94, 652-659	6.4	3
408	Virtual supersampling as post-processing step preserves the trabecular bone morphometry in human peripheral quantitative computed tomography scans. *PLoS ONE*, **2019**, 14, e0212280	3.7	
407	Translation to Practice: Accelerating the Cycle of Innovation to Impact. *Mayo Clinic Proceedings*, **2019**, 94, 490-499	6.4	0
406	Skeletal considerations in the medical treatment of transgender people. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 893-895	18.1	2
405	Increased Cortical Porosity and Reduced Trabecular Density Are Not Necessarily Synonymous With Bone Loss and Microstructural Deterioration. *JBMR Plus*, **2019**, 3, e10078	3.9	16
404	Sex-specific effects of dehydroepiandrosterone (DHEA) on bone mineral density and body composition: A pooled analysis of four clinical trials. *Clinical Endocrinology*, **2019**, 90, 293-300	3.4	16
403	miR-219a-5p Regulates Ror During Osteoblast Differentiation and in Age-related Bone Loss. *Journal of Bone and Mineral Research*, **2019**, 34, 135-144	6.3	24
402	Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 34-43	18.1	139
401	Osteoporosis and Hip Fracture Risk From Routine Computed Tomography Scans: The Fracture, Osteoporosis, and CT Utilization Study (FOCUS). *Journal of Bone and Mineral Research*, **2018**, 33, 1291-1301	6.3	46
400	Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression. *Journal of Bone and Mineral Research*, **2018**, 33, 634-642	6.3	30
399	Evaluation of cross-sectional and longitudinal changes in volumetric bone mineral density in postmenopausal women using single- versus dual-energy quantitative computed tomography. *Bone* , **2018**, 112, 145-152	4.7	17
398	Net ankle quasi-stiffness is influenced by walking speed but not age for older adult women. *Gait and Posture*, **2018**, 62, 311-316	2.6	11
397	The trabecular effect: A population-based longitudinal study on age and sex differences in bone mineral density and vertebral load bearing capacity. *Clinical Biomechanics*, **2018**, 55, 73-78	2.2	8
396	Inhibiting Cellular Senescence: A New Therapeutic Paradigm for Age-Related Osteoporosis. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 1282-1290	5.6	70
395	Validation of a novel, rapid, high precision sclerostin assay not confounded by sclerostin fragments. *Bone*, **2018**, 111, 36-43	4.7	8
394	Regulation of Bone Metabolism by Sex Steroids. *Cold Spring Harbor Perspectives in Medicine*, **2018**, 8,	5.4	89
393	Factors associated with proximal femur fracture determined in a large cadaveric cohort. *Bone*, **2018** , 116, 196-202	4.7	15

392	Sympathetic β1-adrenergic signaling contributes to regulation of human bone metabolism. *Journal of Clinical Investigation*, **2018**, 128, 4832-4842	15.9	44
391	Senolytics improve physical function and increase lifespan in old age. *Nature Medicine*, **2018**, 24, 1246-1256	36.5	776
390	Advancing the Science of Healthcare Service Delivery: The NHLBI Corporate Healthcare LeadersP Panel. *Global Heart*, **2018**, 13, 339-345	2.9	3
389	Sex Steroids and the Pathogenesis of Osteoporosis **2018**, 412-418		1
388	Aging, Obesity, and the Incidence of Diverticulitis: A Population-Based Study. *Mayo Clinic Proceedings*, **2018**, 93, 1256-1265	6.4	22
387	Glycemic Control and Bone Turnover in Older Mexican Americans with Type 2 Diabetes. *Journal of Osteoporosis*, **2018**, 2018, 7153021	2.8	4
386	The relationships between compensatory stepping thresholds and measures of gait, standing postural control, strength, and balance confidence in older women. *Gait and Posture*, **2018**, 65, 74-80	2.6	11
385	Osteoprotection Through the Deletion of the Transcription Factor Rorβ in Mice. *Journal of Bone and Mineral Research*, **2018**, 33, 720-731	6.3	11
384	Legumain Regulates Differentiation Fate of Human Bone Marrow Stromal Cells and Is Altered in Postmenopausal Osteoporosis. *Stem Cell Reports*, **2017**, 8, 373-386	8	40
383	The comparability of HR-pQCT bone measurements is improved by scanning anatomically standardized regions. *Osteoporosis International*, **2017**, 28, 2115-2128	5.3	28
382	Clinical, cellular, microscopic, and ultrastructural studies of a case of fibrogenesis imperfecta ossium. *Bone Research*, **2017**, 5, 16057	13.3	5
381	Addressing the Crisis in the Treatment of Osteoporosis: A Path Forward. *Journal of Bone and Mineral Research*, **2017**, 32, 424-430	6.3	91
380	The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA. *Osteoporosis International*, **2017**, 28, 1225-1232	5.3	64
379	Hormonal and systemic regulation of sclerostin. *Bone*, **2017**, 96, 8-17	4.7	43
378	Bone diseases: Romosozumab - on track or derailed?. *Nature Reviews Endocrinology*, **2017**, 13, 697-698	15.2	18
377	New hope for symptom management during natural and iatrogenic menopause transitions. *Biology of Reproduction*, **2017**, 97, 177-178	3.9	4
376	Targeting cellular senescence prevents age-related bone loss in mice. *Nature Medicine*, **2017**, 23, 1072-1079	36.5	464
375	Fracture Incidence and Characteristics in Young Adults Aged 18 to 49 Years: A Population-Based Study. *Journal of Bone and Mineral Research*, **2017**, 32, 2347-2354	6.3	23

374	The circumstances, orientations, and impact locations of falls in community-dwelling older women. *Archives of Gerontology and Geriatrics*, **2017**, 73, 240-247	4	35
373	Response to Stoecker et al. *Journal of Bone and Mineral Research*, **2017**, 32, 1388	6.3	
372	Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned. *Endocrine Reviews*, **2017**, 38, 325-350	27.2	114
371	Osteoporosis treatment: recent developments and ongoing challenges. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 898-907	18.1	315
370	Statistical Parametric Mapping of HR-pQCT Images: A Tool for Population-Based Local Comparisons of Micro-Scale Bone Features. *Annals of Biomedical Engineering*, **2017**, 45, 949-962	4.7	8
369	Circulating osteogenic endothelial progenitor cell counts: new biomarker for the severity of coronary artery disease. *International Journal of Cardiology*, **2017**, 227, 833-839	3.2	16
368	The Limited Clinical Utility of Testosterone, Estradiol, and Sex Hormone Binding Globulin Measurements in the Prediction of Fracture Risk and Bone Loss in Older Men. *Journal of Bone and Mineral Research*, **2017**, 32, 633-640	6.3	27
367	Operator variability in scan positioning is a major component of HR-pQCT precision error and is reduced by standardized training. *Osteoporosis International*, **2017**, 28, 245-257	5.3	24
366	Determinants of bone strength and quality in diabetes mellitus in humans. *Bone*, **2016**, 82, 28-34	4.7	109
365	Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 Diabetes. *Diabetes* , **2016**, 65, 1757-66	0.9	93
364	Quantification of GDF11 and Myostatin in Human Aging and Cardiovascular Disease. *Cell Metabolism*, **2016**, 23, 1207-1215	24.6	139
363	Voxel size dependency, reproducibility and sensitivity of an in vivo bone loading estimation algorithm. *Journal of the Royal Society Interface*, **2016**, 13, 20150991	4.1	15
362	Osteoclast TGF-Receptor Signaling Induces Wnt1 Secretion and Couples Bone Resorption to Bone Formation. *Journal of Bone and Mineral Research*, **2016**, 31, 76-85	6.3	50
361	Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways. *Journal of Bone and Mineral Research*, **2016**, 31, 65-75	6.3	89
360	Comprehensive Assessment of Osteoporosis and Bone Fragility with CT Colonography. *Radiology*, **2016**, 278, 172-80	20.5	42
359	A randomised controlled trial of low-dose aspirin for the prevention of fractures in healthy older people: protocol for the ASPREE-Fracture substudy. *Injury Prevention*, **2016**, 22, 297-301	3.2	3
358	Bone Quality in Type 2 Diabetes Mellitus **2016**, 211-224		2
357	Identification of Senescent Cells in the Bone Microenvironment. *Journal of Bone and Mineral Research*, **2016**, 31, 1920-1929	6.3	214

356	Microarchitecture and Peripheral BMD are Impaired in Postmenopausal White Women With Fracture Independently of Total Hip T-Score: An International Multicenter Study. *Journal of Bone and Mineral Research*, **2016**, 31, 1158-66	6.3	59
355	Deletion of Estrogen Receptor Beta in Osteoprogenitor Cells Increases Trabecular but Not Cortical Bone Mass in Female Mice. *Journal of Bone and Mineral Research*, **2016**, 31, 606-14	6.3	28
354	Hdac3 Deficiency Increases Marrow Adiposity and Induces Lipid Storage and Glucocorticoid Metabolism in Osteochondroprogenitor Cells. *Journal of Bone and Mineral Research*, **2016**, 31, 116-28	6.3	44
353	Can vitamin D metabolite measurements facilitate a "treat-to-target" paradigm to guide vitamin D supplementation?. *Osteoporosis International*, **2015**, 26, 1655-60	5.3	18
352	The Achilles heel of senescent cells: from transcriptome to senolytic drugs. *Aging Cell*, **2015**, 14, 644-58	9.9	987
351	Global transcriptional profiling using RNA sequencing and DNA methylation patterns in highly enriched mesenchymal cells from young versus elderly women. *Bone*, **2015**, 76, 49-57	4.7	27
350	Clinical Use of Quantitative Computed Tomography-Based Advanced Techniques in the Management of Osteoporosis in Adults: the 2015 ISCD Official Positions-Part III. *Journal of Clinical Densitometry*, **2015**, 18, 393-407	3.5	69
349	Clinical Use of Quantitative Computed Tomography-Based Finite Element Analysis of the Hip and Spine in the Management of Osteoporosis in Adults: the 2015 ISCD Official Positions-Part II. *Journal of Clinical Densitometry*, **2015**, 18, 359-92	3.5	83
348	Osteogenic monocytes within the coronary circulation and their association with plaque vulnerability in patients with early atherosclerosis. *International Journal of Cardiology*, **2015**, 181, 57-64	3.2	24
347	Parathyroid Hormone in the Pathophysiology of Osteoporosis **2015**, 827-835		
346	New Insights Into Androgen and Estrogen Receptor Regulation of the Male Skeleton. *Journal of Bone and Mineral Research*, **2015**, 30, 1134-7	6.3	39
345	Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay. *Skeletal Muscle*, **2015**, 5, 21	5.1	54
344	Response to Wnt Signaling Pathways. *Journal of Bone and Mineral Research*, **2015**, 30, 2135-6	6.3	1
343	Ability of circulating human hematopoietic lineage negative cells to support hematopoiesis. *Journal of Cellular Biochemistry*, **2015**, 116, 58-66	4.7	2
342	Regarding "True Gold or Pyrite: A Review of Reference Point Indentation for Assessing Bone Mechanical Properties In Vivo". *Journal of Bone and Mineral Research*, **2015**, 30, 2325-6	6.3	8
341	Skeletal changes through the lifespan--from growth to senescence. *Nature Reviews Endocrinology*, **2015**, 11, 513-21	15.2	77
340	Clinical Use of Quantitative Computed Tomography (QCT) of the Hip in the Management of Osteoporosis in Adults: the 2015 ISCD Official Positions-Part I. *Journal of Clinical Densitometry*, **2015**, 18, 338-58	3.5	70
339	Effects of Age and Estrogen on Skeletal Gene Expression in Humans as Assessed by RNA Sequencing. *PLoS ONE*, **2015**, 10, e0138347	3.7	43

338	Automatic multi-parametric quantification of the proximal femur with quantitative computed tomography. *Quantitative Imaging in Medicine and Surgery*, **2015**, 5, 552-68	3.6	22
337	The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. *Osteoporosis International*, **2014**, 25, 1439-43	5.3	331
336	Isolation and characterization of human osteoblasts from needle biopsies without in vitro culture. *Osteoporosis International*, **2014**, 25, 887-95	5.3	17
335	Seeding Open Innovation Drug Discovery and Translational Collaborations to Leverage Government Funding: A Case Study of Strategic Partnership between Sanford-Burnham and Mayo Clinic **2014**, 451-486		
334	Cortical porosity identifies women with osteopenia at increased risk for forearm fractures. *Journal of Bone and Mineral Research*, **2014**, 29, 1356-62	6.3	136
333	Effects of estrogen on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in postmenopausal women. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E81-8	5.6	56
332	Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. *Bone*, **2014**, 59, 1-6	4.7	79
331	Diminished bone strength is observed in adult women and men who sustained a mild trauma distal forearm fracture during childhood. *Journal of Bone and Mineral Research*, **2014**, 29, 2193-202	6.3	19
330	Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics. *Molecular Endocrinology*, **2014**, 28, 1740-51		37
329	Validation of a CT-derived method for osteoporosis screening in IBD patients undergoing contrast-enhanced CT enterography. *American Journal of Gastroenterology*, **2014**, 109, 401-8	0.7	42
328	Coronary microvascular endothelial dysfunction is an independent predictor of development of osteoporosis in postmenopausal women. *Vascular Health and Risk Management*, **2014**, 10, 533-8	4.4	25
327	Dissection of estrogen receptor alpha signaling pathways in osteoblasts using RNA-sequencing. *PLoS ONE*, **2014**, 9, e95987	3.7	20
326	Novel anthropomorphic hip phantom corrects systemic interscanner differences in proximal femoral vBMD. *Physics in Medicine and Biology*, **2014**, 59, 7819-34	3.8	9
325	Body composition during childhood and adolescence: relations to bone strength and microstructure. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 4641-8	5.6	38
324	Bone strength and structural deficits in children and adolescents with a distal forearm fracture resulting from mild trauma. *Journal of Bone and Mineral Research*, **2014**, 29, 590-9	6.3	57
323	Priscilla Chen 1944–2013. *Journal of Bone and Mineral Research*, **2014**, 29, 517-517	6.3	
322	In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. *Journal of Bone and Mineral Research*, **2014**, 29, 787-95	6.3	338
321	Mutual enhancement of differentiation of osteoblasts and osteocytes occurs through direct cell-cell contact. *Journal of Cellular Biochemistry*, **2014**, 115, 2039-44	4.7	15

320	Osteoporosis detection in postmenopausal women using axial transmission multi-frequency bone ultrasonometer: clinical findings. *Ultrasonics*, **2014**, 54, 1170-7	3.5	19
319	Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. *Lancet Oncology, The*, **2014**, 15, 474-82	21.7	38
318	Trends in fracture incidence: a population-based study over 20 years. *Journal of Bone and Mineral Research*, **2014**, 29, 581-9	6.3	196
317	Estrogen Deficiency, Postmenopausal Osteoporosis, and Age-Related Bone Loss **2013**, 1113-1136		4
316	TGF- induces Wnt10b in osteoclasts from female mice to enhance coupling to osteoblasts. *Endocrinology*, **2013**, 154, 3745-52	4.8	57
315	Polyphenol-rich cranberry juice has a neutral effect on endothelial function but decreases the fraction of osteocalcin-expressing endothelial progenitor cells. *European Journal of Nutrition*, **2013**, 52, 289-96	5.2	54
314	Identification of Ror targets in cultured osteoblasts and in human bone. *Biochemical and Biophysical Research Communications*, **2013**, 440, 768-73	3.4	11
313	The Role of Sex Steroids in the Pathogenesis of Osteoporosis **2013**, 367-375		5
312	Relationship of adiposity to bone volumetric density and microstructure in men and women across the adult lifespan. *Bone*, **2013**, 55, 119-25	4.7	49
311	Transforming growth factor beta 1 induces CXCL16 and leukemia inhibitory factor expression in osteoclasts to modulate migration of osteoblast progenitors. *Bone*, **2013**, 57, 68-75	4.7	52
310	Longitudinal changes in lumbar bone mineral density distribution may increase the risk of wedge fractures. *Clinical Biomechanics*, **2013**, 28, 10-4	2.2	12
309	Structural patterns of the proximal femur in relation to age and hip fracture risk in women. *Bone*, **2013**, 57, 290-9	4.7	34
308	Effects of bisphosphonate treatment on circulating osteogenic endothelial progenitor cells in postmenopausal women. *Mayo Clinic Proceedings*, **2013**, 88, 46-55	6.4	30
307	Three-dimensional structural analysis of the proximal femur in an age-stratified sample of women. *Bone*, **2013**, 55, 179-88	4.7	27
306	Pathogenesis of age-related bone loss in humans. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2013**, 68, 1226-35	6.4	133
305	Osteonecrosis of the Jaw and Atypical Femoral Fractures **2013**, 1873-1908		2
304	Sphingosine 1-phosphate (S1P) receptors 1 and 2 coordinately induce mesenchymal cell migration through S1P activation of complementary kinase pathways. *Journal of Biological Chemistry*, **2013**, 288, 5398-406	5.4	58
303	Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material Strength. *Journal of Medical Devices, Transactions of the ASME*, **2013**, 7, 410051-410056	1.3	48

302	Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E249-57	5.6	33
301	Improved fracture risk assessment based on nonlinear micro-finite element simulations from HRpQCT images at the distal radius. *Journal of Bone and Mineral Research*, **2013**, 28, 2601-8	6.3	35
300	A distal forearm fracture in childhood is associated with an increased risk for future fragility fractures in adult men, but not women. *Journal of Bone and Mineral Research*, **2013**, 28, 1751-9	6.3	31
299	Multicenter precision of cortical and trabecular bone quality measures assessed by high-resolution peripheral quantitative computed tomography. *Journal of Bone and Mineral Research*, **2013**, 28, 524-36	6.3	89
298	Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization. *Journal of Cellular Biochemistry*, **2013**, 114, 1901-1907	4.7	49
297	Proximal femoral density distribution and structure in relation to age and hip fracture risk in women. *Journal of Bone and Mineral Research*, **2013**, 28, 537-46	6.3	58
296	Bone microarchitecture in ankylosing spondylitis and the association with bone mineral density, fractures, and syndesmophytes. *Arthritis Research and Therapy*, **2013**, 15, R179	5.7	74
295	Sclerostin levels during growth in children. *Osteoporosis International*, **2012**, 23, 1123-30	5.3	58
294	Relationship of femoral neck areal bone mineral density to volumetric bone mineral density, bone size, and femoral strength in men and women. *Osteoporosis International*, **2012**, 23, 155-62	5.3	35
293	Emerging role of circulating calcifying cells in the bone-vascular axis. *Circulation*, **2012**, 125, 2772-81	16.7	66
292	Benefits and risks of bisphosphonate therapy for osteoporosis. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 2272-82	5.6	190
291	Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. *Lancet Oncology, The*, **2012**, 13, 275-84	21.7	90
290	Characterization of mesenchymal progenitor cells isolated from human bone marrow by negative selection. *Bone*, **2012**, 50, 804-10	4.7	36
289	Skeletal muscle mass is associated with bone geometry and microstructure and serum insulin-like growth factor binding protein-2 levels in adult women and men. *Journal of Bone and Mineral Research*, **2012**, 27, 2159-69	6.3	79
288	Male osteoporosis. *Endocrinology and Metabolism Clinics of North America*, **2012**, 41, 629-41	5.5	53
287	Estrogen and the skeleton. *Trends in Endocrinology and Metabolism*, **2012**, 23, 576-81	8.8	394
286	Role of circulating osteogenic progenitor cells in calcific aortic stenosis. *Journal of the American College of Cardiology*, **2012**, 60, 1945-53	15.1	59
285	Potential Extensions of the US FRAX Algorithm. *Journal of Osteoporosis*, **2012**, 2012, 528790	2.8	13

284	Sex- and age-related differences in bone microarchitecture in men relative to women assessed by high-resolution peripheral quantitative computed tomography. *Journal of Osteoporosis*, **2012**, 2012, 129760	2.8	21
283	Relationship of age to bone microstructure independent of areal bone mineral density. *Journal of Bone and Mineral Research*, **2012**, 27, 637-44	6.3	101
282	Examination of nuclear receptor expression in osteoblasts reveals Ror as an important regulator of osteogenesis. *Journal of Bone and Mineral Research*, **2012**, 27, 891-901	6.3	30
281	Odanacatib: location and timing are everything. *Journal of Bone and Mineral Research*, **2012**, 27, 506-8	6.3	25
280	Fracture risk in women with breast cancer: a population-based study. *Journal of Bone and Mineral Research*, **2012**, 27, 1196-205	6.3	31
279	Assessing fracture risk using gradient boosting machine (GBM) models. *Journal of Bone and Mineral Research*, **2012**, 27, 1397-404	6.3	33
278	A DNA binding mutation in estrogen receptor- leads to suppression of Wnt signaling via catenin destabilization in osteoblasts. *Journal of Cellular Biochemistry*, **2012**, 113, 2248-55	4.7	12
277	TGF- mediates suppression of adipogenesis by estradiol through connective tissue growth factor induction. *Endocrinology*, **2012**, 153, 254-63	4.8	30
276	Age-dependent renal cortical microvascular loss in female mice. *American Journal of Physiology - Endocrinology and Metabolism*, **2012**, 302, E979-86	6	20
275	Examination of ER signaling pathways in bone of mutant mouse models reveals the importance of ERE-dependent signaling. *Endocrinology*, **2012**, 153, 5325-33	4.8	16
274	Patients with an HbA1c in the prediabetic and diabetic range have higher numbers of circulating cells with osteogenic and endothelial progenitor cell markers. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 4761-8	5.6	31
273	Insulin-mediated FFA suppression is associated with triglyceridemia and insulin sensitivity independent of adiposity. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 4130-8	5.6	16
272	Osteocalcin positive CD133+/CD34-/KDR+ progenitor cells as an independent marker for unstable atherosclerosis. *European Heart Journal*, **2012**, 33, 2963-9	9.5	60
271	Relationship of sympathetic activity to bone microstructure, turnover, and plasma osteopontin levels in women. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 4219-27	5.6	45
270	Better tools for assessing osteoporosis. *Journal of Clinical Investigation*, **2012**, 122, 4323-4	15.9	11
269	Osteoporosis update from the 2010 santa fe bone symposium. *Journal of Clinical Densitometry*, **2011**, 14, 1-21	3.5	8
268	The Role of the Immune System in the Development of Osteoporosis **2011**, 269-299		1
267	Effects of physiological variations in circulating insulin levels on bone turnover in humans. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 1450-5	5.6	53

266	Distinct effects of loss of classical estrogen receptor signaling versus complete deletion of estrogen receptor alpha on bone. *Bone*, **2011**, 49, 208-16	4.7	24
265	Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. *Bone*, **2011**, 49, 202-7	4.7	67
264	Effects of intermittent parathyroid hormone treatment on osteoprogenitor cells in postmenopausal women. *Bone*, **2011**, 49, 349-55	4.7	28
263	Emerging therapeutic opportunities for skeletal restoration. *Nature Reviews Drug Discovery*, **2011**, 10, 141-56	64.1	108
262	Osteoporosis: now and the future. *Lancet, The*, **2011**, 377, 1276-87	40	1443
261	What accounts for rib fractures in older adults?. *Journal of Osteoporosis*, **2011**, 2011, 457591	2.8	22
260	Human immunodeficiency virus envelope protein Gp120 induces proliferation but not apoptosis in osteoblasts at physiologic concentrations. *PLoS ONE*, **2011**, 6, e24876	3.7	5
259	Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1 levels in patients with MGUS. *Blood*, **2011**, 118, 6529-34	2.2	55
258	The bone and beyond: a shift in calcium. *Nature Medicine*, **2011**, 17, 430-1	50.5	25
257	Robust QCT/FEA models of proximal femur stiffness and fracture load during a sideways fall on the hip. *Annals of Biomedical Engineering*, **2011**, 39, 742-55	4.7	174
256	Trabecular bone deficits among Vietnamese immigrants. *Osteoporosis International*, **2011**, 22, 1627-31	5.3	2
255	Determinants of forearm strength in postmenopausal women. *Osteoporosis International*, **2011**, 22, 3047-54	5.3	6
254	Towards a diagnostic and therapeutic consensus in male osteoporosis. *Osteoporosis International*, **2011**, 22, 2789-98	5.3	94
253	Induction of fracture repair by mesenchymal cells derived from human embryonic stem cells or bone marrow. *Journal of Orthopaedic Research*, **2011**, 29, 1804-11	3.8	21
252	Regulation of circulating sclerostin levels by sex steroids in women and in men. *Journal of Bone and Mineral Research*, **2011**, 26, 27-34	6.3	172
251	Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. *Journal of Bone and Mineral Research*, **2011**, 26, 373-9	6.3	263
250	The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed?. *Journal of Bone and Mineral Research*, **2011**, 26, 441-51	6.3	235
249	Association of hip strength estimates by finite-element analysis with fractures in women and men. *Journal of Bone and Mineral Research*, **2011**, 26, 1593-600	6.3	92

248	Fracture risk in men with prostate cancer: a population-based study. *Journal of Bone and Mineral Research*, **2011**, 26, 1808-15	6.3	32
247	Relationship of testosterone and osteocalcin levels during growth. *Journal of Bone and Mineral Research*, **2011**, 26, 2212-6	6.3	65
246	Estrogen inhibits Dlk1/FA1 production: a potential mechanism for estrogen effects on bone turnover. *Journal of Bone and Mineral Research*, **2011**, 26, 2548-51	6.3	18
245	Is vitamin D a determinant of muscle mass and strength?. *Journal of Bone and Mineral Research*, **2011**, 26, 2860-71	6.3	84
244	Wnt10b activates the Wnt, notch, and NFB pathways in U2OS osteosarcoma cells. *Journal of Cellular Biochemistry*, **2011**, 112, 1392-402	4.7	39
243	The oxysterol, 27-hydroxycholesterol, links cholesterol metabolism to bone homeostasis through its actions on the estrogen and liver X receptors. *Endocrinology*, **2011**, 152, 4691-705	4.8	76
242	What do we tell our patients about calcium and vitamin D supplementation?. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 69-71	5.6	9
241	Is nitroglycerin a novel and inexpensive treatment for osteoporosis?. *JAMA - Journal of the American Medical Association*, **2011**, 305, 826-7	27.4	13
240	Nonoxidative free fatty acid disposal is greater in young women than men. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 541-7	5.6	40
239	Fat tissue, aging, and cellular senescence. *Aging Cell*, **2010**, 9, 667-84	9.9	645
238	Effects of estrogen and testosterone on resting energy expenditure in older men. *Obesity*, **2010**, 18, 2392-4	8	9
237	Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 5063-8	5.6	74
236	Update in male osteoporosis. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 3-10	5.6	129
235	Coronary endothelial dysfunction in humans is associated with coronary retention of osteogenic endothelial progenitor cells. *European Heart Journal*, **2010**, 31, 2909-14	9.5	58
234	Pathogenesis of Osteoporosis. *Translational Endocrinology & Metabolism*, **2010**, 1, 55-86		13
233	Placebo-controlled trials in osteoporosis--proceeding with caution. *New England Journal of Medicine*, **2010**, 363, 1365-7; discussion e22	59.2	15
232	Update on estrogens and the skeleton. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 3569-77	5.6	121
231	Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 5056-62	5.6	211

230	The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. *Endocrinology*, **2010**, 151, 3675-85	4.8	80
229	Physiology of bone loss. *Radiologic Clinics of North America*, **2010**, 48, 483-95	2.3	162
228	Circulating osteogenic cells: characterization and relationship to rates of bone loss in postmenopausal women. *Bone*, **2010**, 47, 83-92	4.7	32
227	Human embryonic stem cell-derived CD34+ cells function as MSC progenitor cells. *Bone*, **2010**, 47, 718-28	4.7	49
226	Female reproductive system and bone. *Archives of Biochemistry and Biophysics*, **2010**, 503, 118-28	4.1	110
225	Age-dependence of femoral strength in white women and men. *Journal of Bone and Mineral Research*, **2010**, 25, 994-1001	6.3	87
224	Relation of serum serotonin levels to bone density and structural parameters in women. *Journal of Bone and Mineral Research*, **2010**, 25, 415-22	6.3	71
223	Assessing forearm fracture risk in postmenopausal women. *Osteoporosis International*, **2010**, 21, 1161-9	5.3	95
222	Effects of chronic estrogen treatment on modulating age-related bone loss in female mice. *Journal of Bone and Mineral Research*, **2010**, 25, 2438-46	6.3	40
221	Relation of vertebral deformities to bone density, structure, and strength. *Journal of Bone and Mineral Research*, **2010**, 25, 1922-30	6.3	80
220	Concise review: Insights from normal bone remodeling and stem cell-based therapies for bone repair. *Stem Cells*, **2010**, 28, 2124-8	5.8	67
219	Modulators of androgen and estrogen receptor activity. *Critical Reviews in Eukaryotic Gene Expression*, **2010**, 20, 275-94	1.3	6
218	The Role of Wnt-10b in Osteoblast Development. *FASEB Journal*, **2010**, 24, 888.1	0.9	
217	Skeletal consequences of deletion of steroid receptor coactivator-2/transcription intermediary factor-2. *Journal of Biological Chemistry*, **2009**, 284, 18767-77	5.4	21
216	Bisphosphonate associated osteonecrosis of the jaw. *Journal of Rheumatology*, **2009**, 36, 478-90	4.1	131
215	Increasing options for the treatment of osteoporosis. *New England Journal of Medicine*, **2009**, 361, 818-26	59.2	62
214	For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics. *Kidney International*, **2009**, 75, 1071-8	9.9	79
213	Fatty acid metabolism in the elderly: effects of dehydroepiandrosterone and testosterone replacement in hormonally deficient men and women. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 3414-23	5.6	27

212	Higher muscle protein synthesis in women than men across the lifespan, and failure of androgen administration to amend age-related decrements. *FASEB Journal*, **2009**, 23, 631-41	0.9	71
211	Estrogen action on bone marrow osteoclast lineage cells of postmenopausal women in vivo. *Osteoporosis International*, **2009**, 20, 761-9	5.3	13
210	Bone structure at the distal radius during adolescent growth. *Journal of Bone and Mineral Research*, **2009**, 24, 1033-42	6.3	198
209	Assessing the true impact of recurrent fractures on fracture risk. *Journal of Bone and Mineral Research*, **2009**, 24, 1512-4	6.3	1
208	Androgens and bone. *Steroids*, **2009**, 74, 296-305	2.8	161
207	Mesenchymal Stem Cells for Bone Repair and Metabolic Bone Diseases. *Mayo Clinic Proceedings*, **2009**, 84, 893-902	6.4	142
206	New selective estrogen and androgen receptor modulators. *Current Opinion in Rheumatology*, **2009**, 21, 374-9	5.3	30
205	DISORDERS OF CALCIUM METABOLISM AND BONE MINERALIZATION **2009**, 587-609		1
204	Mesenchymal stem cells for bone repair and metabolic bone diseases. *Mayo Clinic Proceedings*, **2009**, 84, 893-902	6.4	73
203	Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. *Journal of Oral and Maxillofacial Surgery*, **2008**, 66, 1320-1; author reply 1321-2	1.8	44
202	Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. *Journal of the American College of Cardiology*, **2008**, 52, 1314-25	15.1	137
201	The skeletal response to estrogen is impaired in female but not in male steroid receptor coactivator (SRC)-1 knock out mice. *Bone*, **2008**, 42, 414-21	4.7	19
200	Estrogen and bone: insights from estrogen-resistant, aromatase-deficient, and normal men. *Bone*, **2008**, 43, 414-7	4.7	33
199	Use of renal function measurements for assessing fracture risk in postmenopausal women. *Mayo Clinic Proceedings*, **2008**, 83, 1231-9	6.4	10
198	Bisphosphonates: mechanism of action and role in clinical practice. *Mayo Clinic Proceedings*, **2008**, 83, 1032-45	6.4	829
197	Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. *Endocrine Reviews*, **2008**, 29, 155-92	27.2	582
196	Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 20764-9	11.5	387
195	Bone growth and turnover in progesterone receptor knockout mice. *Endocrinology*, **2008**, 149, 2383-90	4.8	33

194	Osteoporosis in men. *Endocrine Reviews*, **2008**, 29, 441-64	27.2	278
193	Insulin-like growth factor binding protein-2: a novel regulator of skeletal gender differences?. *Endocrinology*, **2008**, 149, 2048-50	4.8	1
192	A bone structural basis for fracture risk in diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 4804-9	5.6	109
191	Estrogen receptor beta isoform-specific induction of transforming growth factor beta-inducible early gene-1 in human osteoblast cells: an essential role for the activation function 1 domain. *Molecular Endocrinology*, **2008**, 22, 1579-95		42
190	Building bone to reverse osteoporosis and repair fractures. *Journal of Clinical Investigation*, **2008**, 118, 421-8	15.9	282
189	Estrogen Effects on Bone in the Male Skeleton **2008**, 1801-1818		1
188	A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. *Journal of Bone and Mineral Research*, **2008**, 23, 205-14	6.3	383
187	Regulation of bone turnover by sex steroids in men. *Journal of Bone and Mineral Research*, **2008**, 23, 705-14	6.3	31
186	Cost-effective osteoporosis treatment thresholds: the United States perspective. *Osteoporosis International*, **2008**, 19, 437-47	5.3	332
185	Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. *Osteoporosis International*, **2008**, 19, 449-58	5.3	317
184	Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women. *Osteoporosis International*, **2008**, 19, 1323-30	5.3	145
183	Comparison of sex steroid measurements in men by immunoassay versus mass spectroscopy and relationships with cortical and trabecular volumetric bone mineral density. *Osteoporosis International*, **2008**, 19, 1465-71	5.3	64
182	Skeletal stem/osteoprogenitor cells: current concepts, alternate hypotheses, and relationship to the bone remodeling compartment. *Journal of Cellular Biochemistry*, **2008**, 103, 393-400	4.7	55
181	Loss of ERE binding activity by estrogen receptor-alpha alters basal and estrogen-stimulated bone-related gene expression by osteoblastic cells. *Journal of Cellular Biochemistry*, **2008**, 103, 896-907	4.7	19
180	Serum biomarker profile associated with high bone turnover and BMD in postmenopausal women. *Journal of Bone and Mineral Research*, **2008**, 23, 1106-17	6.3	33
179	Fracture risk in type 2 diabetes: update of a population-based study. *Journal of Bone and Mineral Research*, **2008**, 23, 1334-42	6.3	278
178	Abdominal aortic calcification, BMD, and bone microstructure: a population-based study. *Journal of Bone and Mineral Research*, **2008**, 23, 1601-12	6.3	39
177	Estrogen and fracture risk in men. *Journal of Bone and Mineral Research*, **2008**, 23, 1548-51	6.3	34

176	Estrogen, Bone Homeostasis, and Osteoporosis **2008**, 1011-1039		3
175	Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. *Journal of Rheumatology*, **2008**, 35, 1391-7	4.1	111
174	Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. *Diabetes Care*, **2007**, 30, 1972-8	14.6	74
173	Re: "The 3.6 kb DNA fragment from the rat Col1a1 gene promoter drives the expression of genes in both osteoblast and osteoclast lineage cells" by Boban et al. (Bone 39:1302-1312, 2006). *Bone*, **2007**, 40, 1671-2; author reply 1673-4	4.7	1
172	Clinical practice. Osteopenia. *New England Journal of Medicine*, **2007**, 356, 2293-300	59.2	70
171	Are the endocrine societyÃ¢ clinical practice guidelines on androgen therapy in women misguided? A commentary-response. *Journal of Sexual Medicine*, **2007**, 4, 1782-3; author reply 1784-5	1.1	6
170	Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. *Journal of Bone and Mineral Research*, **2007**, 22, 724-9	6.3	165
169	High serum IGFBP-2 is predictive of increased bone turnover in aging men and women. *Journal of Bone and Mineral Research*, **2007**, 22, 799-807	6.3	52
168	Contribution of in vivo structural measurements and load/strength ratios to the determination of forearm fracture risk in postmenopausal women. *Journal of Bone and Mineral Research*, **2007**, 22, 1442-8	6.3	156
167	Structural determinants of vertebral fracture risk. *Journal of Bone and Mineral Research*, **2007**, 22, 1885-92	6.3	159
166	Two years of treatment with dehydroepiandrosterone does not improve insulin secretion, insulin action, or postprandial glucose turnover in elderly men or women. *Diabetes*, **2007**, 56, 753-66	0.9	47
165	Effects of testosterone and estradiol on cutaneous vasodilation during local warming in older men. *American Journal of Physiology - Endocrinology and Metabolism*, **2007**, 293, E1426-9	6	12
164	Effects of loss of classical estrogen response element signaling on bone in male mice. *Endocrinology*, **2007**, 148, 1902-10	4.8	28
163	High-trauma fractures and bone mineral density. *JAMA - Journal of the American Medical Association* , **2007**, 298, 2418-9	27.4	2
162	Characterization of circulating osteoblast lineage cells in humans. *Bone*, **2007**, 40, 1370-7	4.7	120
161	Estrogen and the death of osteoclasts: A fascinating story. *BoneKEy Osteovision*, **2007**, 4, 267-272		3
160	Remodeling and vascular spaces in bone. *Journal of Bone and Mineral Research*, **2007**, 22, 1-6	6.3	121
159	Hormonal and biochemical determinants of trabecular microstructure at the ultradistal radius in women and men. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 885-91	5.6	98

158	Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 1848-54	5.6	88
157	Estrogen receptor isoform-specific regulation of the retinoblastoma-binding protein 1 (RBBP1) gene: roles of AF1 and enhancer elements. *Journal of Biological Chemistry*, **2006**, 281, 28596-604	5.4	22
156	Androgen therapy in women: an Endocrine Society Clinical Practice guideline. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 3697-710	5.6	247
155	DHEA in elderly women and DHEA or testosterone in elderly men. *New England Journal of Medicine*, **2006**, 355, 1647-59	59.2	442
154	Long-term fracture risk among women with proven endometriosis. *Fertility and Sterility*, **2006**, 86, 1576-83	4.8	4
153	Estrogen receptor beta: the antimechanostat?. *Bone*, **2006**, 38, 289; author reply 290	4.7	2
152	Circulating cells with osteogenic potential. *Annals of the New York Academy of Sciences*, **2006**, 1068, 489-97	0.5	65
151	Age- and sex-specific differences in the factor of risk for vertebral fracture: a population-based study using QCT. *Journal of Bone and Mineral Research*, **2006**, 21, 1475-82	6.3	118
150	Does reduced skeletal loading account for age-related bone loss?. *Journal of Bone and Mineral Research*, **2006**, 21, 1847-55	6.3	43
149	The classical estrogen receptor transcriptional pathway. *Clinical Reviews in Bone and Mineral Metabolism*, **2006**, 4, 129-140	2.5	
148	Bone fragility in men--where are we?. *Osteoporosis International*, **2006**, 17, 1577-83	5.3	92
147	Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. *Journal of Bone and Mineral Research*, **2006**, 21, 171-7	6.3	290
146	Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. *Journal of Bone and Mineral Research*, **2006**, 21, 124-31	6.3	440
145	Population-based analysis of the relationship of whole bone strength indices and fall-related loads to age- and sex-specific patterns of hip and wrist fractures. *Journal of Bone and Mineral Research*, **2006**, 21, 315-23	6.3	99
144	Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in women. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 5096-103	5.6	66
143	Pathophysiology of age-related bone loss and osteoporosis. *Endocrinology and Metabolism Clinics of North America*, **2005**, 34, 1015-30, xi	5.5	224
142	Mechanisms of sex steroid effects on bone. *Biochemical and Biophysical Research Communications*, **2005**, 328, 688-96	3.4	295
141	Circulating osteoblast-lineage cells in humans. *New England Journal of Medicine*, **2005**, 352, 1959-66	59.2	332

140	Evaluation of a prediction model for long-term fracture risk. *Journal of Bone and Mineral Research*, **2005**, 20, 551-6	6.3	22
139	Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men. *Journal of Bone and Mineral Research*, **2005**, 20, 730-40	6.3	115
138	Potential role of pancreatic and enteric hormones in regulating bone turnover. *Journal of Bone and Mineral Research*, **2005**, 20, 1497-506	6.3	68
137	Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. *Journal of Bone and Mineral Research*, **2005**, 20, 1992-2001	6.3	62
136	The role of the immune system in the pathophysiology of osteoporosis. *Immunological Reviews*, **2005**, 208, 207-27	11.3	263
135	Bone marrow stromal cells express two distinct splice variants of ER-alpha that are regulated by estrogen. *Journal of Cellular Biochemistry*, **2005**, 94, 88-97	4.7	11
134	Contributions of bone density and structure to fracture risk assessment in men and women. *Osteoporosis International*, **2005**, 16, 460-7	5.3	91
133	Osteoporosis assessment by whole body region vs. site-specific DXA. *Osteoporosis International*, **2005**, 16, 1558-64	5.3	36
132	A randomized placebo-controlled trial of short-term graded transdermal estradiol in healthy gonadotropin-releasing hormone agonist-suppressed pre- and postmenopausal women: effects on serum markers of bone turnover, insulin-like growth factor-I, and osteoclastogenic mediators. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 1953-60	5.6	8
131	Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. *Molecular Endocrinology*, **2005**, 19, 1555-68		118
130	Magic bullets to kill nasty osteoclasts. *Endocrinology*, **2005**, 146, 3233-4	4.8	4
129	Potential Anabolic Effects of Androgens on Bone. *Mayo Clinic Proceedings*, **2004**, 79, S14-S18	6.4	7
128	Relationship of estrogen receptor genotypes to bone mineral density and to rates of bone loss in men. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 1808-16	5.6	60
127	Dose-response of estrogen on bone versus the uterus in ovariectomized mice. *European Journal of Endocrinology*, **2004**, 151, 503-10	6.5	66
126	Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts. *Experimental Hematology*, **2004**, 32, 351-9	3.1	20
125	A potentially deleterious role of IGFBP-2 on bone density in aging men and women. *Journal of Bone and Mineral Research*, **2004**, 19, 1075-83	6.3	59
124	Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. *Journal of Bone and Mineral Research*, **2004**, 19, 1945-54	6.3	643
123	Role of hormonal changes in the pathogenesis of osteoporosis in men. *Calcified Tissue International*, **2004**, 75, 110-3	3.9	29

122	Osteoporosis in men--consensus is premature. *Calcified Tissue International*, **2004**, 75, 120-2	3.9	35
121	A fragment of the hypophosphatemic factor, MEPE, requires inducible cyclooxygenase-2 to exert potent anabolic effects on normal human marrow osteoblast precursors. *Journal of Cellular Biochemistry*, **2004**, 93, 1107-14	4.7	17
120	Effects of loss of steroid receptor coactivator-1 on the skeletal response to estrogen in mice. *Endocrinology*, **2004**, 145, 913-21	4.8	67
119	Fracture risk in monoclonal gammopathy of undetermined significance. *Journal of Bone and Mineral Research*, **2004**, 19, 25-30	6.3	121
118	System for the analysis of whole-bone strength from helical CT images **2004**,		22
117	The Role of Androgens and Estrogens in the Male Skeleton **2004**, 1021-1032		
116	Incidence of childhood distal forearm fractures over 30 years: a population-based study. *JAMA - Journal of the American Medical Association*, **2003**, 290, 1479-85	27.4	338
115	Parathyroid hormone plus alendronate--a combination that does not add up. *New England Journal of Medicine*, **2003**, 349, 1277-9	59.2	62
114	Androgens, estrogens, and bone turnover in men. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 2352; author reply 2352-3	5.6	13
113	Insulin-like growth factor (IGF)-II/IGF-binding proteins in constitutionally tall children. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 1912-3; author reply 1913	5.6	0
112	Effect of estrogen replacement therapy on parathyroid hormone secretion in elderly postmenopausal women. *Menopause*, **2003**, 10, 165-71	2.5	17
111	Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. *Journal of Bone and Mineral Research*, **2003**, 18, 213-21	6.3	177
110	Fracture risk after bilateral oophorectomy in elderly women. *Journal of Bone and Mineral Research*, **2003**, 18, 900-5	6.3	91
109	Surrogates for fracture endpoints in clinical trials. *Journal of Bone and Mineral Research*, **2003**, 18, 1146-9	6.3	28
108	Role of parathyroid hormone in mediating age-related changes in bone resorption in men. *Osteoporosis International*, **2003**, 14, 631-6	5.3	21
107	Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. *Osteoporosis International*, **2003**, 14, 728-33	5.3	66
106	Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. *Journal of Cellular Biochemistry*, **2003**, 89, 180-90	4.7	171
105	Phytoestrogen genistein acts as an estrogen agonist on human osteoblastic cells through estrogen receptors alpha and beta. *Journal of Cellular Biochemistry*, **2003**, 89, 633-46	4.7	96

104	Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta. *Journal of Cellular Biochemistry*, **2003**, 90, 315-26	4.7	130
103	Fracture risk following bilateral orchiectomy. *Journal of Urology*, **2003**, 169, 1747-50	2.5	125
102	The role of estrogens in men and androgens in women. *Endocrinology and Metabolism Clinics of North America*, **2003**, 32, 195-218	5.5	32
101	Estrogen, selective estrogen receptor modulators and now mechanism-specific ligands of the estrogen or androgen receptor?. *Trends in Pharmacological Sciences*, **2003**, 24, 261-3	13.2	10
100	Role of extracellular matrix in insulin-like growth factor (IGF) binding protein-2 regulation of IGF-II action in normal human osteoblasts. *Growth Hormone and IGF Research*, **2003**, 13, 328-35	2	40
99	Mutual antagonism of estrogen receptors alpha and beta and their preferred interactions with steroid receptor coactivators in human osteoblastic cell lines. *Journal of Endocrinology*, **2003**, 176, 349-57	4.7	46
98	Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. *Journal of Clinical Investigation*, **2003**, 111, 1221-30	15.9	257
97	Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. *Journal of Clinical Investigation*, **2003**, 111, 1221-1230	15.9	524
96	The immunosuppressant rapamycin, alone or with transforming growth factor-beta, enhances osteoclast differentiation of RAW264.7 monocyte-macrophage cells in the presence of RANK-ligand. *Calcified Tissue International*, **2002**, 71, 437-46	3.9	51
95	Correlates of osteoprotegerin levels in women and men. *Osteoporosis International*, **2002**, 13, 394-9	5.3	160
94	Oestrogen, bones and men: when testosterone just isn't enough. *Clinical Endocrinology*, **2002**, 56, 291-3	3.4	14
93	Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. *Journal of Bone and Mineral Research*, **2002**, 17, 172-8	6.3	173
92	Estrogen receptor isoform-specific induction of progesterone receptors in human osteoblasts. *Journal of Bone and Mineral Research*, **2002**, 17, 580-92	6.3	36
91	Use of site-specific antibodies to characterize the circulating form of big insulin-like growth factor II in patients with hepatitis C-associated osteosclerosis. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 3867-70	5.6	26
90	Clinical review 144: Estrogen and the male skeleton. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 1443-50	5.6	244
89	Leptin-central or peripheral to the regulation of bone metabolism?. *Endocrinology*, **2002**, 143, 4161-4	4.8	46
88	Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 1550-4	5.6	149
87	Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. *European Journal of Endocrinology*, **2002**, 147, 269-73	6.5	54

86	Sex steroids and the construction and conservation of the adult skeleton. *Endocrine Reviews*, **2002**, 23, 279-302	27.2	1268
85	Subcutaneous administration of insulin-like growth factor (IGF)-II/IGF binding protein-2 complex stimulates bone formation and prevents loss of bone mineral density in a rat model of disuse osteoporosis. *Growth Hormone and IGF Research*, **2002**, 12, 178-83	2	59
84	Secondary osteoporosis and the risk of distal forearm fractures in men and women. *Bone*, **2002**, 31, 119-25	4.7	34
83	Author's Response: Effect of Estrogen Versus Testosterone on Circulating Osteoprotegerin and Other Cytokine Levels in Normal Elderly Men. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 4009-4009	5.6	1
82	Estrogen Effects on Bone in the Male Skeleton **2002**, 1467-1476		4
81	Fracture risk in primary hyperparathyroidism. *Journal of Bone and Mineral Research*, **2002**, 17 Suppl 2, N103-7	6.3	19
80	Estrogens and bone health in men. *Calcified Tissue International*, **2001**, 69, 189-92	3.9	68
79	Regulation of osteoclastogenesis and RANK expression by TGF-beta1. *Journal of Cellular Biochemistry*, **2001**, 83, 320-5	4.7	93
78	Estrogen regulation of human osteoblast function is determined by the stage of differentiation and the estrogen receptor isoform. *Journal of Cellular Biochemistry*, **2001**, 83, 448-62	4.7	68
77	Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. *Journal of Bone and Mineral Research*, **2001**, 16, 2118-25	6.3	86
76	Leptin reduces ovariectomy-induced bone loss in rats. *Endocrinology*, **2001**, 142, 3546-53	4.8	236
75	Minireview: the OPG/RANKL/RANK system. *Endocrinology*, **2001**, 142, 5050-5	4.8	1071
74	Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. *Biochemical and Biophysical Research Communications*, **2001**, 280, 334-9	3.4	180
73	Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. *Bone*, **2001**, 29, 114-20	4.7	218
72	Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 3555-61	5.6	420
71	The Type I/Type II Model for Involutional Osteoporosis **2001**, 49-58		14
70	Androgens and Androgenic Progestins **2001**, 709-723		
69	Parathyroid Function in the Normal Aging Process **2001**, 835-842		2

68	Cytokine-specific induction of the TGF-beta inducible early gene (TIEG): regulation by specific members of the TGF-beta family. *Journal of Cellular Biochemistry*, **2000**, 78, 380-90	4.7	40
67	The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. *Journal of Bone and Mineral Research*, **2000**, 15, 2-12	6.3	861
66	Effects of body size and skeletal site on the estimated prevalence of osteoporosis in women and men. *Osteoporosis International*, **2000**, 11, 977-83	5.3	79
65	Epidemiology of Sarcopenia. *Mayo Clinic Proceedings*, **2000**, 75, S10-S13	6.4	63
64	Primary Osteoporosis in Men: Role of Sex Steroid Deficiency. *Mayo Clinic Proceedings*, **2000**, 75, S46-S50	6.4	13
63	The Effects of Androgens on Osteoblast Function In Vitro. *Mayo Clinic Proceedings*, **2000**, 75, S51-S54	6.4	3
62	Senile Osteoporosis **2000**, 225-236		
61	The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. *Endocrinology*, **2000**, 141, 4768-76	4.8	230
60	Relationship of serum leptin levels with body composition and sex steroid and insulin levels in men and women. *Metabolism: Clinical and Experimental*, **2000**, 49, 1278-84	12.7	148
59	Fractures following thyroidectomy in women: a population-based cohort study. *Bone*, **2000**, 27, 695-700	4.7	22
58	Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. *Journal of Hepatology*, **2000**, 33, 878-82	13.4	64
57	Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. *Journal of Clinical Investigation*, **2000**, 106, 1553-60	15.9	537
56	Relationship of Intestinal Calcium Absorption to 1,25-Dihydroxyvitamin D [1,25(OH)2D] Levels in Young Versus Elderly Women: Evidence for Age-Related Intestinal Resistance to 1,25(OH)2D Action. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 4023-4027	5.6	95
55	Immunoradiometric Assay for Intact Human Osteocalcin(1–49) without Cross-Reactivity to Breakdown Products. *Clinical Chemistry*, **1999**, 45, 526-531	5.5	9
54	Response of bipotential human marrow stromal cells to insulin-like growth factors: effect on binding protein production, proliferation, and commitment to osteoblasts and adipocytes. *Endocrinology*, **1999**, 140, 5036-44	4.8	72
53	Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. *Endocrinology*, **1999**, 140, 5579-86	4.8	75
52	The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. *Molecular Endocrinology*, **1999**, 13, 819-28		195
51	Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. *Endocrinology*, **1999**, 140, 4367-70	4.8	529

50	Androgen effects on bone metabolism: recent progress and controversies. *European Journal of Endocrinology*, **1999**, 140, 271-86	6.5	96
49	Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. *Endocrinology*, **1999**, 140, 4382-9	4.8	582
48	Primary hyperparathyroidism and the risk of fracture: a population-based study. *Journal of Bone and Mineral Research*, **1999**, 14, 1700-7	6.3	277
47	Osteology: further debate. *Journal of Bone and Mineral Research*, **1999**, 14, 1017	6.3	
46	The anti-androgen hydroxyflutamide and androgens inhibit interleukin-6 production by an androgen-responsive human osteoblastic cell line. *Journal of Bone and Mineral Research*, **1999**, 14, 1330-7	6.3	56
45	Secondary osteoporosis and the risk of vertebral deformities in women. *Bone*, **1999**, 24, 49-55	4.7	56
44	Fracture risk after surgery for peptic ulcer disease: a population-based cohort study. *Bone*, **1999**, 25, 61-7	4.7	35
43	Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. *Bone*, **1999**, 25, 255-9	4.7	518
42	The assembly of the adult skeleton during growth and maturation: implications for senile osteoporosis. *Journal of Clinical Investigation*, **1999**, 104, 671-2	15.9	38
41	Estrogens and Bone Health **1999**, 275-298		
40	Reply : unitary model of osteoporosis revisited. *Journal of Bone and Mineral Research*, **1998**, 13, 1955	6.3	2
39	A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. *Journal of Bone and Mineral Research*, **1998**, 13, 763-73	6.3	782
38	Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line. *Journal of Cellular Biochemistry*, **1998**, 71, 96-108	4.7	42
37	Fracture risk among patients with urolithiasis: a population-based cohort study. *Kidney International*, **1998**, 53, 459-64	9.9	114
36	Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 2266-74	5.6	918
35	Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. *Biochemical and Biophysical Research Communications*, **1998**, 250, 776-81	3.4	261
34	Survival after the diagnosis of hyperparathyroidism: a population-based study. *American Journal of Medicine*, **1998**, 104, 115-22	2.4	210
33	Effects of the circadian variation in serum cortisol on markers of bone turnover and calcium homeostasis in normal postmenopausal women. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 751-6	5.6	69

32	Effects of the Circadian Variation in Serum Cortisol on Markers of Bone Turnover and Calcium Homeostasis in Normal Postmenopausal Women. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 751-756	5.6	64
31	A Defect in Renal Calcium Conservation May Contribute to the Pathogenesis of Postmenopausal Osteoporosis. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 1916-1920	5.6	25
30	Relationship of Serum Sex Steroid Levels and Bone Turnover Markers with Bone Mineral Density in Men and Women: A Key Role for Bioavailable Estrogen. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 2266-2274	5.6	621
29	Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line **1998**, 71, 96		1
28	Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 1522-7	5.6	182
27	Genetic testing in medullary thyroid carcinoma syndromes: mutation types and clinical significance. *Mayo Clinic Proceedings*, **1997**, 72, 430-6	6.4	34
26	Hepatitis C-associated osteosclerosis: an unusual syndrome of acquired osteosclerosis in adults. *American Journal of Medicine*, **1997**, 103, 70-3	2.4	26
25	Is familial hyperparathyroidism a unique disease?. *Surgery*, **1997**, 122, 1028-33	3.6	28
24	Relationship of bone turnover to bone density and fractures. *Journal of Bone and Mineral Research*, **1997**, 12, 1083-91	6.3	255
23	Development and characterization of a conditionally immortalized human osteoblastic cell line stably transfected with the human androgen receptor gene. *Journal of Cellular Biochemistry*, **1997**, 66, 542-51	4.7	16
22	Idiopathic Osteoporosis--Is the Osteoblast To Blame?. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 2792-2794	5.6	28
21	Relationship between body composition and bone mass in women. *Journal of Bone and Mineral Research*, **1996**, 11, 857-63	6.3	220
20	Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism. *Kidney International*, **1996**, 50, 1663-71	9.9	55
19	Cytokine production in the bone marrow microenvironment: failure to demonstrate estrogen regulation in early postmenopausal women. *Journal of Clinical Endocrinology and Metabolism*, **1996**, 81, 513-518	5.6	43
18	Role of calcium intake in modulating age-related increases in parathyroid function and bone resorption. *Journal of Clinical Endocrinology and Metabolism*, **1996**, 81, 1699-1703	5.6	154
17	Role of biochemical markers in assessment of osteoporosis. *Acta Orthopaedica*, **1995**, 66, 14-18		3
16	Treatment options for osteoporosis. *Mayo Clinic Proceedings*, **1995**, 70, 978-82	6.4	16
15	Circulating levels of cytokines that modulate bone resorption: effects of age and menopause in women. *Journal of Bone and Mineral Research*, **1994**, 9, 1313-8	6.3	79

14	Epidemiology and clinical features of osteoporosis in young individuals. *Bone*, **1994**, 15, 551-5	4.7	138
13	Identification of multiple endocrine neoplasia, type 2 gene carriers using linkage analysis and analysis of the RET proto-oncogene. *Journal of Clinical Endocrinology and Metabolism*, **1994**, 78, 1261-1264	5.6	21
12	Abnormalities of parathyroid hormone secretion in elderly women that are reversible by short term therapy with 1,25-dihydroxyvitamin D3. *Journal of Clinical Endocrinology and Metabolism*, **1994**, 79, 211-216	5.6	50
11	Circulating cytokine levels in osteoporotic and normal women. *Journal of Clinical Endocrinology and Metabolism*, **1994**, 79, 707-711	5.6	69
10	Muscle strength in osteoporotic versus normal women. *Osteoporosis International*, **1993**, 3, 8-12	5.3	81
9	Expression of a potential metastasis suppressor gene (nm23) in thyroid neoplasms. *World Journal of Surgery*, **1993**, 17, 615-20; discussion 620-1	3.3	13
8	Clinical performance of parathyroid hormone immunometric assays. *Mayo Clinic Proceedings*, **1992**, 67, 637-45	6.4	67
7	Parathyroid hormone-related peptide in lactation and in umbilical cord blood. *Mayo Clinic Proceedings*, **1990**, 65, 1408-14	6.4	52
6	Nucleotide sequence of cloned cDNAs encoding chicken preproparathyroid hormone. *Journal of Bone and Mineral Research*, **1988**, 3, 689-98	6.3	40
5	Autoimmune hemolytic anemia with both cold and warm autoantibodies. *JAMA - Journal of the American Medical Association*, **1985**, 254, 1175-6	27.4	4
4	beta-Lactamase proceeds via an acyl-enzyme intermediate. Interaction of the Escherichia coli RTEM enzyme with cefoxitin. *Biochemistry*, **1980**, 19, 2895-901	3.2	218
3	Minireview: The OPG/RANKL/RANK System		329
2	ST-V-Net: incorporating shape prior into convolutional neural networks for proximal femur segmentation. *Complex & Intelligent Systems*,1	7.1	1
1	Chapter 41. Role of Sex Steroids in the Pathogenesis of Osteoporosis208-213		3